Toll-like receptor 4 genetic variation and advanced prostate cancer risk
Toll-like receptor 4 genetic variation and advanced prostate cancer risk
复制标题
DOI：
10.1158/1055-9965.epi-06-0429
复制
发表时间：
2007-02-01
影响因子：
3.8
通讯作者：
Witte, John S.
中科院分区：
文献类型：
--
作者：
Cheng, Iona;Plummer, Sarah J.;Witte, John S.
Toll样受体4（TLR4）是一种关键的先天免疫受体，主要针对革兰氏阴性菌启动炎症反应。最近的两篇出版物报道，TLR4的变异与前列腺癌的风险有关。为了进一步研究TLR4在前列腺癌易感性中的作用，我们确定了6个标记单核苷酸多态性，这些多态性全面捕获了该基因座的常见遗传变异，并在我们对1，012名男性的病例对照研究中测试了这些多态性。两个单核苷酸多态性与前列腺癌风险具有名义上的统计学显著相关性，其中最强的（rs10759932）与疾病风险增加4倍相关（P = 0.006）。我们通过排列分析估计，类似的强结果将偶然发生2.5%的时间。我们的研究结果支持以前的研究，并表明TLR4的遗传差异影响前列腺癌的风险。
Toll-like receptor 4 (TLR4) is a key innate immunity receptor that initiates an inflammatory response primarily against Gram-negative bacteria. Two recent publications reported that variants in TLR4 were associated with risk of prostate cancer. To further investigate the role of TLR4 in prostate cancer susceptibility, we identified six tagging single-nucleotide polymorphisms that comprehensively captured the common genetic variation of the locus and tested these polymorphisms in our case-control study of 1,012 men. Two single-nucleotide polymorphisms showed nominally statistically significant associations with prostate cancer risk, with the strongest (rs10759932) associated with a 4-fold increased risk of disease (P = 0.006). We estimated through permutation analysis that a similarly strong result would occur by chance 2.5% of the time. Our findings support previous studies and suggest that inherited differences in TLR4 influence prostate cancer risk.